2025 HCPCS Code Q2041
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
TAGS: axicabtagene viable positive preparation leukapheresis autologous therapeutic million| Short Description | Axicabtagene ciloleucel car+ |
| HCPCS Action Code | N - No maintenance for this code |
| HCPCS Coverage Code | C - Carrier judgment |
| HCPCS Code Added Date | April 01, 2018 |
| HCPCS Action Effective Date | January 01, 2019 |
| HCPCS Pricing Indicator Code | 51 - Drugs |
| HCPCS Type Of Service Code | 1 - Medical care |
| HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
| HCPCS Anesthesia Base Unit Quantity | 0 |
| HCPCS Coverage Issues Manual Reference Section Number |
Check Similar HCPCS Codes
- Q4333 - Ardeograft, per sq cm
- Q5001 - Hospice or home hlth in home
- Q5002 - Hospice/home hlth in asst lv
- Q5003 - Hospice in lt/non-skilled nf
- Q5004 - Hospice in snf
- Q5005 - Hospice, inpatient hospital
- Q5006 - Hospice in hospice facility
- Q5007 - Hospice in ltch
- Q5008 - Hospice in inpatient psych
- Q5009 - Hospice/home hlth, place nos
- Q5010 - Hospice home care in hospice
- Q5101 - Injection, zarxio
- Q5102 - Inj., infliximab biosimilar
- Q5103 - Injection, inflectra
- Q5104 - Injection, renflexis
- Q5105 - Inj retacrit esrd on dialysi
- Q5106 - Inj retacrit non-esrd use
- Q5107 - Inj mvasi 10 mg
- Q5108 - Injection, fulphila
- Q5109 - Injection, ixifi, 10 mg